A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1

Grants and Contracts Details

StatusFinished
Effective start/end date5/27/21 → 6/7/25

Funding

  • Pharmaceutical Research Associates: $101,960.00